Arriving in the field of weight management treatment, retatrutide presents a different approach. Beyond many current medications, retatrutide operates as a twin agonist, concurrently engaging both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic substance (GIP) binding sites. This dual activation fosters multiple helpful effects